OTCMKTS:HYPMY

Hypera Stock Forecast, Price & News

$6.73

-0.31 (-4.40 %)

(As of 06/11/2021 03:56 PM ET)

Add

Compare

Today's Range

$6.73

▼

$7.03

50-Day Range

$5.80

▼

$7.49

52-Week Range

$4.33

▼

$7.76

Volume5,300 shs

Average Volume12,645 shs

Market Capitalization$4.26 billion

P/E Ratio16.83

Dividend Yield2.08%

Beta0.96

30 days | 90 days | 365 days | Advanced Chart

Receive HYPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands; dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. The company also provides nutrition, sweeteners, and vitamin supplement products under the Tamarine, Vitasay 50+, BiotÃ´nico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo QuÃmica, Torsilax, Neosoro, Doralgina, Flavonid, and Histamin brands. It sells its products through distributors and wholesalers. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in SÃ£o Paulo, Brazil.

Short Interest in Hypera S.A. (OTCMKTS:HYPMY) Grows By 117.2%
May 28, 2021 | americanbankingnews.com

Hypera (OTCMKTS:HYPMY) Stock Price Down 0.9%
May 26, 2021 | americanbankingnews.com

Brazil antitrust regulator clears hurdle for Hypera-Takeda deal
January 20, 2021 | reuters.com

Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio
October 29, 2020 | seekingalpha.com

Takeda Executing On Synergies And Asset Sales, But Not Getting Much Credit
October 1, 2020 | seekingalpha.com

Brazil's Hypera to sell Xantinon drug to Uniao Quimica
September 26, 2020 | finance.yahoo.com

ZIM Lab signs pact with Hypera Pharma to market vitamin D3 orally dispersible film in Brazil
August 19, 2020 | in.finance.yahoo.com

Brazilian drugmaker Hypera cuts 2020 revenue outlook
July 24, 2020 | finance.yahoo.com

UPDATE 1-Brazil's Hypera says 'irregular payments' will be reimbursed, shares jump
May 26, 2020 | www.reuters.com

Brazil's Hypera says internal probe found $20 mln in 'irregular payments'
May 26, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HYPMY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.hyperapharma.com.br
Phone55-11-3627-4206
Employees8,918
Year FoundedN/A

Sales & Book Value

Annual Sales$793.81 million
Price / Sales5.37
Cash Flow$0.44 per share
Price / Cash Flow15.22
Book Value$2.83 per share
Price / Book2.38

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares633,421,000
Market Cap$4.26 billion
Next Earnings Date7/23/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.94 out of 5 stars

Medical Sector

1164th out of 2,099 stocks

Pharmaceutical Preparations Industry

534th out of 831 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Hypera.

2.6 Community Rank

Outperform Votes
Hypera has received 155 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hypera has received 142 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hypera has received 52.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hypera and other stocks. Vote “Outperform” if you believe HYPMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HYPMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
Hypera pays a meaningful dividend of 2.08%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Hypera does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hypera insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.17% of the stock of Hypera is held by institutions.

1.3 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Hypera is 16.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 20.78.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hypera is 16.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.97.
Price to Book Value per Share Ratio
Hypera has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Hypera (OTCMKTS:HYPMY) Frequently Asked Questions

Is Hypera a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hypera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Hypera stock.
View analyst ratings for Hypera or view top-rated stocks.

What stocks does MarketBeat like better than Hypera?

Wall Street analysts have given Hypera a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hypera wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hypera?

Hypera saw a increase in short interest in May. As of May 14th, there was short interest totaling 6,300 shares, an increase of 117.2% from the April 29th total of 2,900 shares. Based on an average daily volume of 9,100 shares, the days-to-cover ratio is currently 0.7 days.
View Hypera's Short Interest.

When is Hypera's next earnings date?

Hypera is scheduled to release its next quarterly earnings announcement on Friday, July 23rd 2021.
View our earnings forecast for Hypera.

How were Hypera's earnings last quarter?

Hypera S.A. (OTCMKTS:HYPMY) posted its quarterly earnings data on Friday, April, 23rd. The company reported $0.09 earnings per share (EPS) for the quarter. The company earned $214.21 million during the quarter. Hypera had a trailing twelve-month return on equity of 14.80% and a net margin of 30.68%.
View Hypera's earnings history.

How has Hypera's stock been impacted by Coronavirus (COVID-19)?

Hypera's stock was trading at $6.98 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HYPMY stock has decreased by 3.6% and is now trading at $6.73.
View which stocks have been most impacted by COVID-19.

Is Hypera a good dividend stock?

Hypera pays an annual dividend of $0.14 per share and currently has a dividend yield of 2.08%.
View Hypera's dividend history.

Who are Hypera's key executives?

Hypera's management team includes the following people:

Mr. Breno Toledo Pires de Oliveira, Chief Exec. Officer
Mr. Adalmario Ghovatto Satheler do Couto, Investor Relations Officer & CFO
Mr. Carlos Roberto Scorsi, Chief Operating officer (Age 59)
Juliana Aguinaga DamiÃ£o Salem, Chief Legal & Compliance Officer
Mr. Luiz Eduardo Sales Clavis, Commercial & Marketing VP
Mr. Claudio Bergamo dos Santos, Pres of Pharma & Director (Age 56)
Mr. Martim Prado Mattos, Sec. (Age 41)
Mr. Luiz Eduardo Violland, Chief Exec. Officer of the Pharmaceutical Division

Who are some of Hypera's key competitors?

Some companies that are related to Hypera include Zai Lab (ZLAB), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Maravai LifeSciences (MRVI), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR) and Ascendis Pharma A/S (ASND).
View all of HYPMY's competitors.

What is Hypera's stock symbol?

Hypera trades on the OTCMKTS under the ticker symbol "HYPMY."

How do I buy shares of Hypera?

Shares of HYPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hypera's stock price today?

One share of HYPMY stock can currently be purchased for approximately $6.73.

How much money does Hypera make?

Hypera has a market capitalization of $4.26 billion and generates $793.81 million in revenue each year.

How many employees does Hypera have?

Hypera employs 8,918 workers across the globe.

What is Hypera's official website?

The official website for Hypera is www.hyperapharma.com.br.

Where are Hypera's headquarters?

Hypera is headquartered at AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120.

How can I contact Hypera?

Hypera's mailing address is AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120. The company can be reached via phone at 55-11-3627-4206 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here